Who owns Lakefront Biotherapeutics NV, from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).
Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.
Madison Avenue International LP: 5.5% · 3,606,203 shares — Madison Avenue Partners, LP: 5.5% · 3,606,203 shares — EMAI Management, LLC: 5.5% · 3,606,203 shares
TANG CAPITAL MANAGEMENT, LLC: 8.4% · 5,559,674 shares — KEVIN TANG: 8.4% · 5,559,674 shares — TANG CAPITAL PARTNERS, LP: 5.0% · 3,313,189 shares
2 more 5% stakes behind a free account
See every investor who has disclosed crossing 5% of Lakefront Biotherapeutics NV.
Sign up freeEvery institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of Lakefront Biotherapeutics NV they hold. Together these 113 managers report 50.04% of shares outstanding.
| Investor | Position value | Shares | % of their portfolio | % of company | As of |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | $500M | 16,707,477 | 30.34% | 25.35% | June 30, 2026 |
| TANG CAPITAL MANAGEMENT LLC | $114M | 3,785,991 | 5.16% | 5.75% | June 30, 2026 |
111 more institutional holders behind a free account
See every manager reporting Lakefront Biotherapeutics NV, how much of the company they hold, and how big the position is inside their own portfolio.
Sign up freeFunds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 23 funds hold 2.67% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.
| Fund | Position value | % of net assets | % of company | As of |
|---|---|---|---|---|
| Columbia Overseas Value Fund | $24.1M | 0.35% | 1.08% | February 28, 2026 |
| Columbia Variable Portfolio - Overseas Core Fund | $8.4M | 0.22% | 0.43% | June 30, 2026 |
21 more funds behind a free account
See every fund holding Lakefront Biotherapeutics NV and what share of its net assets the position represents.
Sign up freeLoading...
